Medical Doctor Program year 2019 Source: CMS Open Payments, 2026 publication

Mitchell Dunn

Cardiovascular Disease Washington, DC Medical Doctor

NPI 1730282377 CMS profile 1209663

2021 K Street Nw, Suite 512, Washington, DC 20006

Open in the dashboard

General payments

$13

1 record reported · program year 2019

Research payments

$0

Paid to them · None reported · program year 2019

Ownership & investment interest

$0

None reported

Through program year 2019, Mitchell Dunn of Washington, DC is reported in the CMS Open Payments database as having received $13 across 1 general payment and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 1st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2019 General $13 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mitchell Dunn
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Mitchell Dunn were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Mitchell Dunn Cardiovascular Disease median Middle half National median
2019 $13 $450 $127–$1,392 $163
2020 $0 $242 $77–$751 $114
2021 $0 $335 $101–$1,037 $132
2022 $0 $395 $121–$1,211 $149
2023 $0 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program year 2019
  1. Novo Nordisk Inc $13 1 payment

Every payment, record by record

What the payments were for General payments · program year 2019
  1. Food and Beverage $13 1 payment
Products named General payments · program year 2019
  1. Saxenda $13 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

1,877

Median for Internal Medicine: 777

Drug cost

$199,783

Median for Internal Medicine: $73,373

Branded share of claims

15.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 54 $46,909
Eliquis Apixaban Brand 32 $29,929
Prolia Denosumab Brand 13 $23,241
Farxiga Dapagliflozin Propanediol Brand 12 $18,662
Mounjaro Tirzepatide Brand 12 $18,225
Repatha Sureclick Evolocumab Brand 20 $16,832
Candesartan Cilexetil Generic 62 $6,346
Rosuvastatin Calcium Generic 208 $4,122
Synthroid Levothyroxine Sodium Brand 38 $3,124
Ezetimibe Generic 63 $3,022

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2019

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record